Neurolixis Inc. has been awarded a $861,000 grant by the US Department of Defense Congressionally Directed Medical Research Program to investigate the effects of NLX-112 as a potential treatment for Machado Joseph disease, a serious and rare genetic movement disorder. NLX-112 is an exceptionally-selective and efficacious serotonin 5-HT1A receptor agonist which has already shown promising activity in models of Parkinson's disease. It is anticipated that NLX-112 could also be beneficial for treatment of other movement disorders, including Machado Joseph disease.

Read the full press release here.

United States Department of Defense Seal.svg

 

Newsletter

Please enable the javascript to submit this form

Follow Neurolixis on: